• Ernest Dodoo, Beate Huffmann, Inti Peredo, Hanne Grinaker, Georges Sinclair, Theofilos Machinis, Per Oyvind Enger, Bente Sandvei Skeie, Paal-Henning Pedersen, Marcus Ohlsson, Abiel Orrego, Thomas Kraepelien, Pierre Barsoum, Hamza Benmakhlouf, Lars Herrman, Mikael Svensson, and Bodo Lippitz.
• Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden. Electronic address: ernest.dodoo@karolinska.se.
• World Neurosurg. 2014 Nov 1; 82 (5): e623-32.

ObjectiveThe current study retrospectively assessed delayed gamma knife radiosurgery (GKRS) in the management of high-grade glioma recurrences.MethodsA total of 55 consecutive patients with high-grade glioma comprising 68 World Health Organization (WHO) III and WHO IV were treated with GKRS for local recurrences between 2001 and 2007. All patients had undergone microsurgery and radiochemotherapy, considered as standard therapy for high-grade glioma. Complete follow-up was available in all patients; median follow-up was 17.2 months (2.5-114.2 months). Median tumor volume was 5.2 mL, prescription dose was 20 Gy (14-22 Gy), and median max dose was 45 Gy (30-77.3 Gy).ResultsThe patients with WHO III tumors showed a median survival of 49.6 months with and a 2-year survival of 90%. After GKRS of the recurrences, these patients showed a median survival of 24.2 months and a 2-year survival of 50%. The patients with WHO IV tumors had a median survival of 24.5 months with a 2-year survival of 51.4%. After the recurrence was treated with GKRS, the median survival was 11.3 months and a 2-year survival: 22.9% for the WHO IV patients.ConclusionThe current study shows a survival benefit for high-grade glioma recurrences when GKRS was administered after standard therapy. This is a relevant improvement compared with earlier studies that had had not been able to provide a beneficial effect timing radiosurgery in close vicinity to EBRT.Copyright © 2014 Elsevier Inc. All rights reserved.

40 keywords...

hide…